A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma
โ Scribed by Mulatero, C.W.; Penson, R.T.; Papamichael, D.; Gower, N.H.; Evans, M.; Rudd, R.M.
- Book ID
- 118569451
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- English
- Weight
- 62 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0169-5002
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide. Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated.
## Background: The prognosis associated with malignant pleural mesothelioma (mpm) is poor in spite of surgery, radiotherapy, photodynamic therapy, or chemotherapy. therefore, new therapeutic strategies, including intrapleural immunotherapy, are being investigated. several clinical studies have demo
## Stage I Renal Cell Carcinoma I read the report by Kinouchi et al., 1 in which they concluded that the tumor grading of renal cell carcinoma was not predictive of the survival of Robson Stage I patients. This does not mean that the three-grading system is worthless; the authors simply showed tha